Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Chloroquine
Drug ID BADD_D00440
Description Chloroquine is an aminoquinolone derivative first developed in the 1940s for the treatment of malaria.[A191655] It was the drug of choice to treat malaria until the development of newer antimalarials such as [pyrimethamine], [artemisinin], and [mefloquine].[A191787] Chloroquine and its derivative [hydroxychloroquine] have since been repurposed for the treatment of a number of other conditions including HIV, systemic lupus erythematosus, and rheumatoid arthritis.[A192432] **The FDA emergency use authorization for [hydroxychloroquine] and chloroquine in the treatment of COVID-19 was revoked on 15 June 2020.[L14312]** Chloroquine was granted FDA Approval on 31 October 1949.[L12054]
Indications and Usage For the suppressive treatment and for acute attacks of malaria due to P. vivax, P.malariae, P. ovale, and susceptible strains of P. falciparum, Second-line agent in treatment of Rheumatoid Arthritis
Marketing Status Not Available
ATC Code P01BA01
DrugBank ID DB00608
KEGG ID D02366
MeSH ID D002738
PubChem ID 2719
TTD Drug ID D09EGZ
NDC Product Code Not Available
Synonyms Chloroquine | Chlorochin | Chingamin | Khingamin | Nivaquine | Chloroquine Sulfate | Sulfate, Chloroquine | Chloroquine Sulphate | Sulphate, Chloroquine | Aralen | Arequin | Arechine
Chemical Information
Molecular Formula C18H26ClN3
CAS Registry Number 54-05-7
SMILES CCN(CC)CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.0020.000699%
Abnormal dreams17.15.02.001; 19.02.03.0010.000466%Not Available
Agitation19.06.02.001; 17.02.05.012--
Agranulocytosis01.02.03.001--Not Available
Alopecia23.02.02.001--
Anaemia01.03.02.0010.000699%
Anaphylactic shock10.01.07.002; 24.06.02.004--Not Available
Anaphylactoid reaction24.06.03.007; 10.01.07.003--Not Available
Angioedema23.04.01.001; 10.01.05.009--Not Available
Anxiety19.06.02.002--
Aplastic anaemia01.03.03.002--Not Available
Asthenia08.01.01.0010.000466%Not Available
Atrioventricular block02.03.01.0020.000699%Not Available
Atrioventricular block complete02.03.01.0030.001864%
Atrophy08.03.04.001--Not Available
Blindness17.17.01.003; 06.02.02.0010.000466%Not Available
Blood creatine phosphokinase increased13.04.01.0010.000466%
Blood pressure decreased13.14.03.0020.000466%Not Available
Bradycardia02.03.02.0020.000466%Not Available
Cardiac arrest02.03.04.0010.000182%
Cardiac failure02.05.01.0010.000365%
Cardiac failure congestive02.05.01.0020.000932%Not Available
Cardio-respiratory arrest02.03.04.002; 22.02.06.0070.000304%Not Available
Cardiogenic shock24.06.02.006; 02.05.01.0030.001864%Not Available
Cardiomegaly02.04.02.0010.000122%Not Available
Cardiomyopathy02.04.01.0010.000932%Not Available
Cataract subcapsular06.06.01.0020.000466%Not Available
Cerebral ischaemia17.08.01.005; 24.04.06.0030.000466%
Coma17.02.09.0010.000699%Not Available
Completed suicide19.12.01.001; 08.04.01.0100.000304%Not Available
The 1th Page    1 2 3 4 5    Next   Last    Total 5 Pages